Skip to main content
SpringerLink
Log in

Receptor-Selective Retinoids for Psoriasis

Focus on Tazarotene

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Topical and oral retinoids have been successfully used in antipsoriatic therapy over the last 50 years. Development of more selective agents has led to an improved efficacy and safety profile.

The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene. Topical tazarotene displays an onset of action and efficacy similar to those of other established antipsoriatic agents. Common adverse events of this agent such as pruritus, burning, local skin irritation, and erythema are limited to the skin and generally mild or moderate in severity. Although effective as monotherapy, evidence is accumulating that combining topical tazarotene with other established antipsoriatic therapies results in enhanced efficacy and reduced adverse events. In particular, concomitant use of topical tazarotene with a mid-potency or high-potency corticosteroid in the treatment of psoriatic plaques enhances efficacy and reduces the risk of corticosteroid-induced skin atrophy. Combination of phototherapy with tazarotene accelerates the clinical response and diminishes the cumulative UVB or psoralen plus UVA (PUVA) exposure load. Recently, an oral form of tazarotene has been developed. The results of completed phase III clinical trials of this agent indicate a beneficial effect in moderate to severe plaque psoriasis. Adverse events are generally of mild severity, and most of those observed, such as cheilitis and dry skin, are typical of hypervitaminosis A. Of note, oral tazarotene appears not to be associated with other adverse events that are typical of oral retinoids, including hypertriglyceridemia and hypercholesterolemia. However, since head-to-head trials with acitretin (the only retinoid currently approved for systemic therapy) have not been conducted, it is unclear whether tazarotene is any safer or more effective than acitretin. Moreover, the major drawback of oral tazarotene is teratogenicity, which may limit its use in female patients. Further studies evaluating long-term clinical outcomes with oral tazarotene and its use in combination therapies are awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1

Similar content being viewed by others

References

  1. Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 2005 Aug; 6 (10): 1725-34

    Article  PubMed  CAS  Google Scholar 

  2. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004 Feb; 50 (2): 301-9

    Article  PubMed  Google Scholar 

  3. Ho VC. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 2004 May; 150 Suppl. 67: 1-10

    Article  PubMed  CAS  Google Scholar 

  4. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003 Oct; 25 (10): 2487-505

    Article  PubMed  CAS  Google Scholar 

  5. Allergan, Inc. Allergan receives written response from FDA on oral tazarotene [online]. Available from URL: http://www.shareholder.com/agn/ReleaseDetail.cfm?ReleaseID=164878 [Accessed 2006 Mar 20]

  6. Trends-in-Medicine. FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee meeting on Allergan’s Tazoral for moderate-to-severe psoriasis; Gaithersburg, Maryland; July 12, 2004. [online]. Available from URL: http://www.trends-in-medicine.com/July2004/FDAtazora1074p.pdf [Accessed 2006 Mar 20]

  7. Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf 2005; 4 (1): 129-38

    Article  PubMed  Google Scholar 

  8. Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol 2005; 6 (4): 255-72

    Article  PubMed  Google Scholar 

  9. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000 Jun; 6 (9): 919-31

    Article  PubMed  CAS  Google Scholar 

  10. Fisher GJ, Talwar HS, Xiao JH, et al. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 1994 Aug 12; 269 (32): 20629-35

    PubMed  CAS  Google Scholar 

  11. Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord 2001 Aug; 1 (2): 153-64

    Article  PubMed  CAS  Google Scholar 

  12. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999 Oct; 37 (4): 273-87

    Article  PubMed  CAS  Google Scholar 

  13. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and API antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995 Jan 13; 270 (2): 923-7

    Article  PubMed  CAS  Google Scholar 

  14. Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994 Dee; 6 (6: 825-31

  15. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996 May 3; 85: 403-14

    Article  PubMed  CAS  Google Scholar 

  16. Liu PT, Krutzik SR, Kim J, et al. Cutting edge: all-trans retinoic acid downregulates TLR2 expression and function. J Immuno12005 Mar 1; 174: 2467-70

  17. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994 Apr; 30: 581-90

    Article  PubMed  CAS  Google Scholar 

  18. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002 Jan; 41: 41-55

    Article  PubMed  Google Scholar 

  19. Niles RM. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother 2002 Mar; 3: 299-303

    Article  PubMed  CAS  Google Scholar 

  20. Nagpal S, Patel S, Asano AT, et al. Tazarotene-induced gene 1 (TIGI), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol 1996 Feb; 106: 269-74

    Article  PubMed  CAS  Google Scholar 

  21. Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997 Jul; 109: 91-5

    Article  PubMed  CAS  Google Scholar 

  22. DiSepio D, Ghosn C, Eckert RL, et al. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Nall Acad Sci U S A 1998 Dee 8; 95: 14811-5

  23. Orlandi A, Bianchi L, Costanzo A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol 2004 Apr; 122: 1037-41

    Article  PubMed  CAS  Google Scholar 

  24. Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004 Jul; 151: 148-56

    Article  PubMed  CAS  Google Scholar 

  25. Papoutsaki M, Lanza M, Marinari B, et al. The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. J Invest Dermato12004 Dee; 123:1162-8

  26. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997 Jul; 37: 85-92

    Article  PubMed  CAS  Google Scholar 

  27. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1 % applied once daily for 12 weeks. J Am Acad Dermatol 2003 May; 48: 760-7

    Article  PubMed  Google Scholar 

  28. Allergan, Inc. TazoralTM for the treatment of moderate to very severe plaque psoriasis: briefing document prepared by Allergan for the Dermatologic and Ophthalmic Drugs Advisory Committee and Drug Safety and Risk Manage ment Advisory Committee meeting [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefmg/2004-4062B101Allergan-Background.pdf [Accessed 2006 Mar 13]

  29. Attar M, Yu D, Ni J, et al. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans. J Pharm Sci 2005; 94 (10): 2246-55

    Article  PubMed  CAS  Google Scholar 

  30. Yu Z, Yu D, Walker PS, et al. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. Clin Pharmacokinet 2004; 43: 673-84

    Article  PubMed  CAS  Google Scholar 

  31. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998 Jan; 134: 57-60

    Article  PubMed  CAS  Google Scholar 

  32. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001 Nov; 68: 355-8

    Google Scholar 

  33. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003 Jul; 149: 207-9

    Article  PubMed  CAS  Google Scholar 

  34. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39 (4 Pt 1): 590-6

    Google Scholar 

  35. Gollnick H, Menter A. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999 Apr; 140 Suppl. 54: 18-23

    Article  PubMed  CAS  Google Scholar 

  36. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000 Oct; 22: 1225-38

    Article  PubMed  CAS  Google Scholar 

  37. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001 Mar; 40: 210-2

    Article  PubMed  CAS  Google Scholar 

  38. Lebwohl M, Lombardi K, Tan MIL Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001 Jan; 40: 64-6

    Article  PubMed  CAS  Google Scholar 

  39. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002 Mar; 6: 95-102

    Article  PubMed  Google Scholar 

  40. Behrens S, Grundmann-Kollmann M, Peter RU, et al. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid [letter]. Br J Dermatol 1999 Jul; 141: 177

    Article  PubMed  CAS  Google Scholar 

  41. Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000 Mar; 42: 493-5

    Article  PubMed  CAS  Google Scholar 

  42. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000 Nov; 43: 821-8

    Article  PubMed  CAS  Google Scholar 

  43. Schiener R, Behrens-Williams SC, Pillekamp H, et al. Calcipotriol vs tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. Br J Dermatol 2000 Dee; 143: 1275-8

    Google Scholar 

  44. Tzaneva S, Honigsmann H, Tanew A, et al. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002 Oct; 147: 748-53

    Article  PubMed  CAS  Google Scholar 

  45. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002 Jun; 46: 907-13

    Article  PubMed  Google Scholar 

  46. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58

    Article  PubMed  Google Scholar 

  47. Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermato12001 Jul; 40: 468-71

  48. Poulin YP. Tazarotene 0.1 % gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 1999 Jan; 63: 41-8

    Google Scholar 

  49. Abel EA. Phototherapy: UVB and PUVA. Cutis 1999 Nov; 64: 339–42

    Google Scholar 

  50. Lowe NJ. Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol 1999 Apr; 140 Suppl. 54: 8-11

    Article  PubMed  CAS  Google Scholar 

  51. Taylor CR, Stern RS, Leyden JJ, et al. Photoaging/photodamage and photoprotection. J Am Acad Dermatol 1990 Jan; 22: 1-15

    Article  PubMed  CAS  Google Scholar 

  52. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer 1994 Jun 1; 73: 2759-64

    Article  PubMed  CAS  Google Scholar 

  53. Jensen AM, Llado MB, Skov L, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998 Dee; 139: 984-91

    Google Scholar 

  54. Coynik D. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. Cutis 2000 Dee; 66: 19-24

    Google Scholar 

  55. Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 2000 Jun; 42: 1008-11

    Article  PubMed  CAS  Google Scholar 

  56. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1 % gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001 Jun; 67: 10-6

    Google Scholar 

  57. Bershad S, Kranjac SG, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermato12002 Apr; 138: 481-9

  58. Veraldi S, Schianchi R. Short-contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2003; 206: 347-8

    Article  PubMed  Google Scholar 

  59. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998 May; 38: 705-11

    Article  PubMed  CAS  Google Scholar 

  60. Tzung TY, Wu JC, Hsu NJ, et al. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Acta Derm Venereol 2005; 85: 236-9

    PubMed  CAS  Google Scholar 

  61. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152 (4): 597-615

    Article  PubMed  CAS  Google Scholar 

  62. Sherman SE Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999 Apr 8; 340: 1075-9

    Article  PubMed  CAS  Google Scholar 

  63. Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J Dermatolog Treat 2004 Jan; 15: 8-13

    Article  PubMed  CAS  Google Scholar 

  64. Hotard RS, Feldman SR, Fleischer Jr AB. Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol 2000 Apr; 42: 620-3

    PubMed  CAS  Google Scholar 

  65. Ansley A, Hawk JL. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol 1997 May; 136: 798-9

    Article  Google Scholar 

  66. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999 Sep; 41: S22-4

    Article  PubMed  CAS  Google Scholar 

  67. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999 Sep; 41: S22–4

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Tübingen, Tübingen, Germany

    Günther Weindl & Martin Schaller

  2. Department of Dermatology and Allergology, University of Munich, Frauenlobstrasse 9-11, Munich, D-80337, Germany

    Alexander Roeder & Hans Christian Korting

  3. Institute of Pharmacy, Pharmacology and Toxicology, Free University Berlin, Berlin, Germany

    Monika Schäfer-Korting

Authors
  1. Günther Weindl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Roeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monika Schäfer-Korting
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Schaller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans Christian Korting
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Roeder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weindl, G., Roeder, A., Schäfer-Korting, M. et al. Receptor-Selective Retinoids for Psoriasis. Am J Clin Dermatol 7, 85–97 (2006). https://doi.org/10.2165/00128071-200607020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200607020-00002

Keywords

Search

Navigation